Home Cart Sign in  
Chemical Structure| 1403783-31-2 Chemical Structure| 1403783-31-2

Structure of Nexturastat A
CAS No.: 1403783-31-2

Chemical Structure| 1403783-31-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Nexturastat A is a selective inhibitor of HDAC6 with IC50 of 5 nM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Nexturastat A

CAS No. :1403783-31-2
Formula : C19H23N3O3
M.W : 341.40
SMILES Code : O=C(NO)C1=CC=C(CN(CCCC)C(NC2=CC=CC=C2)=O)C=C1
MDL No. :MFCD28099804
InChI Key :JZWXMCPARMXZQV-UHFFFAOYSA-N
Pubchem ID :71462653

Safety of Nexturastat A

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Nexturastat A

epigenetics

Isoform Comparison

Biological Activity

Target
  • HDAC6

    HDAC6, IC50:5 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
B16 melanoma cells 5 µM 24 hours Nexturastat A repressed IFNγ-driven Cd47 upregulation. PMC10898070
SM1 melanoma cells 5 µM 24 hours Nexturastat A repressed IFNγ-driven Cd47 upregulation. PMC10898070
WM164 human melanoma cells 5 µM 24 hours HDAC6 knockdown downregulated CD47 expression and prevented IFNγ-driven CD47 upregulation. PMC10898070
THP-1-derived macrophages 5 µM 24 hours Nexturastat A significantly upregulated M1-associated markers NOS2, CD86, and IL1B and downregulated M2-associated markers MRC1 and CD209. PMC10898070
A31A7 macrophages 5 µM 24 hours Nexturastat A significantly upregulated surface expression of M1-associated markers Cd80 and H2 and downregulated surface expression of M2-associated marker Cd206. PMC10898070
Bone marrow-derived macrophages (BMDMs) 5 µM 24 hours Nexturastat A significantly upregulated M1-associated markers Nos2 and Cd80 and downregulated M2-associated markers Arg1 and Mrc1 at the transcriptional level. PMC10898070
Mouse peritoneal elicited macrophage (PEM) 5 μM 24 hours To evaluate the effect of Nexturastat A on macrophage polarization, results showed that NextA reduced the expression of M2 marker CD206 and increased the M1 phenotype. PMC6467894
SM1 melanoma cells 2.5 and 5 μM 24 hours To evaluate the effect of Nexturastat A on PD-L1 expression, results showed that NextA neutralized the anti-PD1 antibody-mediated upregulation of IFNγ on PD-L1 production. PMC6467894
OVSAHO 12500 nM 48 h preincubation followed by 72 h incubation Nexturastat A increased cisplatin potency in OVSAHO cells, with IC50 values in the micromolar range. PMC6627993
Kuramochi 5000 nM 48 h preincubation followed by 72 h incubation Nexturastat A increased cisplatin potency in Kuramochi cells, with IC50 values in the micromolar range. PMC6627993
HEY 5000 nM 48 h preincubation followed by 72 h incubation Nexturastat A increased cisplatin potency in HEY cells, with IC50 values in the micromolar range. PMC6627993
CaOV3 7500 nM 48 h preincubation followed by 72 h incubation Nexturastat A increased cisplatin potency in CaOV3 cells, with IC50 values in the micromolar range. PMC6627993
A2780 7500 nM 48 h preincubation followed by 72 h incubation Nexturastat A increased cisplatin potency in A2780 cells, with IC50 values in the micromolar range. PMC6627993
RPMI-8226/BTZ100 cells 20 μM 48 hours To evaluate the effect of NexA on BTZ-resistant cell viability, results showed that NexA remarkably suppressed the viability of RPMI-8226/BTZ100 cells. PMC6430725
U266 cells 30 μM 48 hours To evaluate the effect of NexA on cell viability, results showed that NexA dose-dependently impaired the viability of the two cell lines. PMC6430725
RPMI-8226 cells 30 μM 48 hours To evaluate the effect of NexA on cell viability, results showed that NexA dose-dependently impaired the viability of the two cell lines. PMC6430725
HeLa cells 2.5 µM 72 hours Nexturastat A increased BE3-mediated gene editing efficiency in HeLa cells, with an average improvement of 4.90-fold. PMC8421147
HT1080 cells 2.5 µM 72 hours Nexturastat A significantly improved BE3-mediated gene editing efficiency in HT1080 cells, with an average improvement of 7.96-fold. PMC8421147
HEK-293 cells 2.5 µM 72 hours Nexturastat A increased BE3-mediated gene editing efficiency, with an average improvement of 3.46-fold. PMC8421147
BT474 0.37 nM to 100 µM 72 hours Evaluate the cytotoxic effect of Nexturastat A on HER2+ breast cancer cells, showing that NextA was effective in both SKBR3 and BT474 cell lines. PMC11591923
SKBR3 0.37 nM to 100 µM 72 hours Evaluate the cytotoxic effect of Nexturastat A on HER2+ breast cancer cells, showing that NextA was effective in both SKBR3 and BT474 cell lines, with the lowest IC50 in SKBR3 clones. PMC11591923

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Oct4-eGFP mice Added to embryo culture medium 0.5 µM 24 hours Nexturastat A significantly improved BE3-mediated gene editing efficiency, with a 1.57-fold improvement in embryos. PMC8421147
C57BL/6 mice SM1 melanoma model Subcutaneous injection 15 mg/kg 5 days a week for 25 days To evaluate the effect of Nexturastat A in combination with anti-PD-1 antibody, results showed that the combination significantly reduced tumor growth and enhanced immune cell infiltration. PMC6467894
C57BL/6 mice SM1 melanoma model Intraperitoneally 20 mg/kg Every other day until the end of the study The combination of Nexturastat A and anti-CD47 significantly decreased tumor growth, increased immune cell infiltration in the tumor microenvironment (TME), and modulated macrophage and natural killer (NK) cell populations. PMC10898070
Mice Listeria infection model Intraperitoneal injection 3 mg/kg 5 days post infection Reduced Listeria burdens, increased Th1 cell numbers PMC9613754

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.93mL

0.59mL

0.29mL

14.65mL

2.93mL

1.46mL

29.29mL

5.86mL

2.93mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories